Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium.
Experiments were carried out in canine ventricular trabeculae loaded with aequorin to investigate the effects of levosimendan {(R)-([4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono)-propanedinitrile} on contractile force and Ca(2+) transients in normal and acidotic conditions. The concentration-response curve for the positive inotropic effect (PIE) of levosimendan was bell-shaped, that is, it declined markedly at 10(-4) M after achieving the maximum at 10(-5) M in normal (pH(o)=7.4) and acidotic conditions (pH(o)=6.6). The positive inotropic effect (PIE) of levosimendan up to 10(-5) M was associated with an increase in Ca(2+) transients and a shift of the relationship of Ca(2+) transients and force to the left of that of elevation of [Ca(2+)](o). Levosimendan at 10(-4) M elicited a negative inotropic effect (NIE) in association with a further increase in Ca(2+) transients, and during washout Ca(2+) transients increased further, while the force was abolished before both signals recovered to the control. In acidotic conditions, the relationship of Ca(2+) transients and force during the application of levosimendan in normal conditions was essentially unaltered, whereas the PIE was suppressed due to attenuation of the increase in Ca(2+) transients. In summary, in intact canine ventricular myocardium, levosimendan elicits a dual inotropic effect: at lower concentrations, it induces a PIE by a combination of increases in Ca(2+) transients and Ca(2+) sensitivity, while at higher concentrations it elicits an NIE due to a decrease in Ca(2+) sensitivity. Acidosis inhibits the PIE of levosimendan due to suppression of the increase in Ca(2+) transients in response to the compound.
Takahashi
Reiko
R
Department of Cardiovascular Pharmacology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Endoh
Masao
M
D000138:Acidosis / Q000378:metabolism*; D000331:Aequorin; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects / Q000378:metabolism; D006835:Hydrazones / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D009206:Myocardium / Q000378:metabolism*; D011724:Pyridazines / Q000494:pharmacology*; D000077464:Simendan
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan; D000331:Aequorin; D002118:Calcium